Combination therapy for papillomavirus infection

DOI: https://dx.doi.org/10.18565/aig.2017.12.122-125

Rakhmatulina M.R.

A.I. Burnazyan Federal Medical Biophysical Center, Federal Biomedical Agency of Russia, Moscow 123098, Zhivopisnaya str. 46, Russia
Objective. To analyze the data available in the current literature on the epidemiology, etiology, and treatments of the clinical manifestations of papillomavirus infection. To systematize the results of investigating the clinical efficiency of using inosine pranobex (isoprinosine) in patients with different forms of papillomavirus infection.
Material and methods. Foreign and Russian articles published on the investigation topic were analyzed.
Results. The paper gives an update on the epidemiology, etiology, and treatments of the clinical manifestations of papillomavirus infection. It describes the results of investigating the efficiency of monotherapy and combination treatment for papillomavirus infection with inosine pranobex (isoprinosine).
Conclusion. The current investigations have established the high efficiency of using inosine pranobex to treat human papillomavirus infection: in combination therapy (87.5–97%) and in monotherapy (72.4–95%). There is evidence for an improvement in the regeneration processes in the genital tract mucous membrane when isoprinosine is used after destructive therapy and an increase in the rate of human papillomavirus elimination as a result of the treatment.

References


1. Стерн П.Л., Китченер Г.С. Вакцины для профилактики рака шейки матки. М.: МЕДпресс–информ; 2011. [Stern P.L., Kitchener G.S. Vaccines for the prevention of cervical cancer. Мoscow: MEDpress-inform; 2011. (in Russian)]

2. Костючек И.Н., Миненкова О.А. Диагностика ВПЧ-ассоциированных поражений шейки матки. Справочник заведующего КДЛ. 2012; 11: 21-4. [Kostyuchek I.N., Minenkova O.A. Diagnosis of HPV-associated lesions of the cervix. Directory of the head of KDL. 2012; 11: 21-4. (in Russian)]

3. Маныкин А.А. Папилломавирусы. В кн.: Львов Д.К., ред. Медицинская вирусология. М.: МИА; 2008: 269-76. [Manykin A.A. Papillomaviruses. In: Lvov D.K., ed. Medical virology. Moscow: MIA; 2008: 269-76. (in Russian)]

4. International Human Papillomavirus Reference Center. Human papillomavirus reference clones. 2014. Available at: http://www.hpvcenter.se/html/refclones.html Accessed September 2014.

5. Doorbar J., Quint W., Banks L., Bravo I.G., Stoler M., Broker T.R., Stanley M.A. The biology and life-cycle of human papillomaviruses. Vaccine. 2012; 30(Suppl. 5): F55-70.

6. International Agency for Research on Cancer. Human Papillomaviruses. IARC monographs on the evaluation of carcinogenic risks to humans: A review of human carcinogens: Biological agents. Vol. 100B. Lyon: IARC; 2012. Available at: http://monographs.iarc.fr/ENG/Monographs/vol100B/mono100B-11.pdf Accessed September 2014.

7. Patel H., Wagner M., Singhal P., Kothari S. Systematic review of the incidence and prevalence of genital warts. BMC Infect. Dis. 2013; 13: 39.

8. Аполихина И.А., Денисова Е.Д. Лечебные и профилактические аспекты папилломавирусной инфекции гениталий. Эффективная фармакотерапия в акушерстве и гинекологии. 2009; 1: 26-8. [Apolikhina I.A., Denisova E.D. Therapeutic and preventive aspects of papillomavirus infection of the genitals. Effektivnaya farmakoterapiya v akusherstve i ginekologii. 2009; 1: 26-8. (in Russian)]

9. Баграмова Г.Э., Гуреева М.А., Хлебникова А.Н. Иммуномодулирующая терапия папилломавирусной инфекции. Клиническая дерматология и венерология. 2011; 6: 47-50. [Bagramova G.E., Gureeva M.A., Khlebnikova A.N. Immunomodulatory therapy of papillomavirus infection. Clinical dermatology and. Klinicheskaya dermatologiya i venerologiya. 2011; 6: 47-50. (in Russian)]

10. Рахматулина М.Р., Большенко Н.В., Куевда Д.А. Особенности клинического течения папилломавирусной инфекции в зависимости от генотипа и количественных показателей вирусов папилломы человека высокого онкогенного риска. Вестник дерматологии и венерологии. 2014; 3: 95-105. [Rakhmatulina M.R., Bolshenko N.V., Kuevda D.A. Features of the clinical course of papillomavirus infection depending on the genotype and quantitative indicators of human papillomaviruses of high oncogenic risk. Vestnik dermatologii i venerologii. 2014; 3: 95-105. (in Russian)]

11. Кацамбас А.Д., Лотти Т.М., ред. Европейское руководство по лечению дерматологических болезней. Пер. с англ. 3-е изд. М.: МЕДпресс-информ; 2014. [Katsambas A., Lotti T., Dessinioti C., D’Erme A.M., eds. European handbook of dermatological treatments. 3rd ed. Berlin: Springer; 2015.]

12. Клинические рекомендации РОДВК по ведению больных инфекциями, передаваемыми половым путем, и урогенитальными инфекциями. Издательский дом Деловой Экспресс; 2012: 1-112. [Clinical recommendations of the RODVK for the management of patients with sexually transmitted infections and urogenital infections. Publishing house Business Express; 2012: 1-112. (in Russian)]

13. Прилепская В.Н., Роговская С.И. Возможности Изопринозина в лечении хронических цервицитов и вагинитов. Русский медицинский журнал. 2008; 16(1): 5-9. [Prilepskaya V.N., Rogovskaya S.I. Possibilities of isoprinosine in the treatment of chronic cervicitis and vaginitis. Russian medical journal. 2008; 16 (1): 5-9. (in Russian)]

14. Елисеева М.Ю., Мынбаев О.А. Вспомогательная иммунотерапия ВПЧ-ассоциированных поражений слизистых оболочек и кожи урогенитальной и перианальной локализации (систематический обзор литературы и МЕТА-анализ применения Инозина пранобекса). Гинекология. 2007; 11(5): 22-33. [Eliseeva M.Yu., Myinbaev O.A. Auxiliary immunotherapy of HPV-associated lesions of the mucous membranes and skin of urogenital and perianal localization (systematic review of literature and META-analysis of the use of Inosine pranobeks). Ginekologiya. 2007; 11(5): 22-33. (in Russian)]

15. Линаск Л.И., Григорьева Е.Е. Опыт применения Изопринозина при заболеваниях шейки матки на фоне папилломавирусной инфекции у подростков и молодых женщин. Русский медицинский журнал. 2008; 16(19): 1221-5. [Linask L.I., Grigorieva E.E. Experience in the use of isoprinosine in diseases of the cervix uteri against the background of papillomavirus infection in adolescents and young women. Russian medical journal. 2008; 16 (19): 1221-5. (in Russian)]

16. Долгушина В.Ф., Ахматова АН., Беренда МА. Эффективность изопринозина в лечении хронического цервицита, ассоциированного с папилломавирусной инфекцией. Фарматека. 2009; 14: 75-8. [Dolgushina V.F., Ahmatova AN., Berenda MA. The effectiveness of isoprinosine in the treatment of chronic cervicitis associated with papillomavirus infection. Farmateka. 2009; 14: 75-8. (in Russian)]

17. Tay S.K. Efficacy of inosine pranobex oral therapy in subclinical human papillomavirus infection of vulva: a randomized double-blinded placebo controlled study. Int. J. STD AIDS. 1996; 7(4): 276-80.

18. Mohanty K.C., Scott C.S. Immunotherapy of genital warts with inosine pranobex (Imunovir): preliminary study. Genitourin. Med. 1986; 62(5): 352-5.

Received 08.09.2017

Accepted 22.09.2017


About the Autors


Rakhmatulina Margarita Rafikovna, MD, Professor of the Department of Dermatovenereology and Cosmetology with the Course of Clinical Laboratory Diagnostics,
A.I. Burnazyan Federal Medical Biophysical Center, Federal Biomedical Agency of Russia.
123098, Russia, Moscow, Zhivopisnaya str. 46. Tel.: +79162031003. E-mail: ra.marg@yandex.ru

For citations: Rakhmatulina M.R. Combination therapy for papillomavirus infection. Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2017; (12): 122-5. (in Russian)
https://dx.doi.org/10.18565/aig.2017.12.122-125


Similar Articles

Бионика Медиа